December 3, 2010. My name is Jessica Resas, and I am a lap band patient. In October of 2009, I had a lap band inserted inside me. Now I want my life back.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Testimony at FDA on Gastric LAP-BAND
December 3, 2010. In their newly proposed label, Allergan indicated a “caution” (not a warning) for patients with autoimmune diseases or symptoms, and did NOT mention a family history of those conditions.
Read More »Patient, Consumer, and Public Health Coalition Letter to FDA Commissioner Expressing Concerns about FDA’s Policies and Practices Regarding FDA Advisory Committee Meetings
October 26, 2010. Advisory Committee meetings are a very important way for the FDA to show the public how they make decisions and value input from independent scientific experts and the public.
Read More »NCHR Comments to FDA on Medical Device User Fees (MDUFA)
November 1, 2010. A major concern is that the medical device user fees are too low to adequately support the Center for Devices and Radiological Health’s (CDRH) efforts to clear or approve safe and effective medical devices in a timely manner.
Read More »NCHR Testimony at the FDA Advisory Committee Meeting on Lorcaserin
September 16, 2010. The studies are an important reminder that behavior modification is a safe and effective alternative to diet pills. Lorcaserin does not appear to be effective for most patients, and especially not for most African-American or Latino patients. More extensive research is needed on the risks.
Read More »